Zafgen, Inc., (Nasdaq: ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Equity Offerings

Zafgen (ZFGN) Prices 8M Common Share Offering at $7.50/ShJune 28, 2018 8:01 AM Zafgen Announces Proposed Offering of Common StockJune 27, 2018 4:01 PM